local_hospital

Thermalsole und Schwefelbad Bentheim GmbH

Address
Am Bade 1, 48455 Bad Bentheim, Germany

Atopic Dermatitis and Eczema Research

At Thermalsole und Schwefelbad Bentheim GmbH, a major part of the clinical research portfolio focuses on immune system diseases and skin and connective tissue diseases, especially atopic dermatitis and related eczema conditions. These studies are designed to evaluate new treatment options, compare them with existing therapies, and better understand long-term control of itching and skin inflammation.

  • Moderate-to-severe atopic dermatitis and chronic eczema
  • Testing new therapies and comparing them with established treatments
  • Long-term safety, symptom control, and improvement in skin symptoms

The site’s work in this area includes both adult and pediatric populations, reflecting a broad effort to improve care across age groups.

Psoriasis and Psoriatic Arthritis Studies

Another important research area covers psoriasis and psoriatic arthritis, with trials aimed at both skin symptoms and joint-related disease activity. These studies generally assess whether newer therapies can improve disease control, reduce flare-ups, and offer better outcomes for people living with persistent inflammatory disease.

  • Plaque psoriasis, pustular psoriasis, and palmoplantar pustulosis
  • Psoriatic arthritis and related inflammatory symptoms
  • Evaluating treatment effectiveness and symptom improvement

This research area highlights the clinic’s strong focus on immune-mediated inflammatory conditions and practical treatment advances.

Alopecia Areata and Hair Loss Research

The clinical studies also include hormonal diseases and hair-related disorders, especially alopecia areata and other forms of hair loss. Research at the site is centered on finding treatments that can support hair regrowth, maintain response over time, and improve quality of life for patients affected by visible hair loss.

  • Alopecia areata in children, adolescents, and adults
  • Female androgenetic alopecia and other hair loss conditions
  • Testing therapies intended to stimulate regrowth and sustain benefit

These studies reflect a growing interest in both the medical and psychosocial impact of chronic hair disorders.

Vitiligo and Skin Pigmentation Disorders

Research at the Klinisches Studienzentrum also includes vitiligo, particularly non-segmental forms that affect skin pigmentation. The studies are focused on evaluating whether emerging therapies can help restore pigment, improve visible skin changes, and provide durable disease control.

  • Non-segmental vitiligo in adults and adolescents
  • Improving repigmentation and disease stability
  • Assessing treatment benefit in a chronic visible skin condition

This area adds to the site’s broader expertise in inflammatory and immune-related skin disease research.

Urticaria, Pruritus, and Itch-Driven Conditions

A further focus is on conditions marked by severe itching and recurrent skin symptoms, including chronic spontaneous urticaria, prurigo nodularis, and chronic pruritus-related disorders. These trials aim to improve itch relief, reduce skin lesions, and evaluate how well new treatments can control symptoms that strongly affect daily life.

  • Chronic spontaneous urticaria and chronic pruritus
  • Prurigo nodularis and lichen simplex chronicus
  • Measuring symptom relief and overall treatment effectiveness

At Thermalsole und Schwefelbad Bentheim GmbH, this field supports research into better symptom management for patients with highly burdensome skin disease.

Cutaneous Lupus, Hidradenitis Suppurativa, and Other Immune-Mediated Skin Diseases

The site also participates in studies of less common but clinically significant immune system diseases, including cutaneous lupus erythematosus, hidradenitis suppurativa, and systemic sclerosis-associated interstitial lung disease. These trials are designed to assess whether new or existing therapies can improve disease activity, reduce inflammation, and provide longer-term safety information.

  • Subacute and chronic cutaneous lupus erythematosus
  • Hidradenitis suppurativa and related inflammatory skin disease
  • Evaluating disease control, safety, and durability of response

The breadth of this research shows a strong commitment to complex immune-mediated conditions that often require specialized care.

Actinic Keratosis, Scabies, and Other Dermatology Trials

In addition to chronic inflammatory disorders, the research portfolio includes studies in other skin and connective tissue diseases such as actinic keratosis and scabies. These trials are aimed at evaluating whether treatments can clear affected skin areas more effectively and improve care for common dermatologic conditions.

  • Actinic keratosis of the scalp and face
  • Scabies and other treatable skin infestations
  • Testing treatment effectiveness and skin clearance

This work broadens the site’s dermatology profile beyond inflammatory disease into preventive and therapeutic skin care research.

Site Overview

assignment
108
connected trials
corporate_fare
42
sponsors
science
66
IMPs

Activity Indicator

Last 6 months

14
Trials started
+27% vs previous period.
11
Trials started 6–12 months ago
108
Total trials linked
Highly Active
trending_upGrowing+27%
6
1
4
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 10 therapeutic areas and 15 of 66 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 65 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
35
Sponsors (total)
42
Active sponsors
23

Sponsor Network

Top 23 by active trials.

lock +22 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +20 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
108
Outperforms 98% of sites
public
Therapeutic diversity
10areas
Outperforms 96% of sites
groups
Sponsor diversity
42sponsors
Outperforms 97% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Thermalsole und Schwefelbad Bentheim GmbH

lock Showing 1 of 108 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic DermatitisAlmirall S.A.Phase IIINot RecruitingMay 2023Apr 2026

IMP list

lock Showing 1 of 66 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Amlitelimab6Unknown2022-11-102024-10-30

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.